DADoğukan AKÇAY

Doğukan AKÇAY

*This is an algorithmically generated author record based on publicly available information.

Doğukan AKÇAY has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of Hybrid Techniques with 3D-Conformal Radiotherapy in Patients with Lung Cancer

    by Ömer Azaklioğlu, Doğukan AKÇAY, İlhami Er, Kadir Akgüngör, Ayşe Nur DEMİRAL

    Purpose: It’s postulated that hybrid techniques (HT) with lower weighting of IMRT/VMAT component would improve lung dose-volume parameters despite some disadvantage in PTV homogeneity index (HI) and target coverage (TC). Material and Methods: Conformal plans were prepared using 6-10-15 MV-X photon energies while IMRT/VMAT plans of HTs were prepared using 6MV-X. Four HTs were developed having two different ratios (10% and 50%) of IMRT/VMAT component (h-IMRT1, h-IMRT2 and h-VMAT1, h-VMAT2, respectively). HTs were compared with 3D-CRT in terms of HI and TC for PTV, and total lung (TL) and contralateral lung (CL) V5Gy, V10Gy, V20Gy and mean lung dose (MLD). Results: All HTs were advantageous for HI and TC, while disadvantageous for TL and CL-V5Gy. H-IMRT2 provided better TC than h-IMRT1, and so did h-VMAT2 compared to h-VMAT1. Lower weighting of IMRT/VMAT decreased TL and CL-V5Gy in HTs. In addition, h-IMRT1 decreased TL and CL-MLD and CL-V20Gy compared to h-IMRT2, while h-VMAT2 decreased TL-V20Gy and CL-MLD compared to h-VMAT2. Conclusion: In the RT of lung tumors close to vertebra, it may be appropriate to suggest a ratio of IMRT/VMAT component about 10% in order to decrease the low and intermediate dose-wash lung volume, if HI and TC values are acceptable.

  • EVALUATION OF CLINICAL STUDIES USING KNOWLEDGE BASED PLANNING METHODS IN THE RADIOTHERAPY OF PROSTATE CANCER WITH VOLUMETRIC MODULATED ARC THERAPY

    by Şeyda Kinay, Doğukan AKÇAY, Cenk Umay, Barbaros Aydin, Dilara Gülşan, Kadir Akgüngör, Ayşe Nur DEMİRAL

    Bilgi Tabanlı Planlama (“Knowledge Based Planningˮ-KBP), klinik olarak kabul edilebilir Yoğunluk Ayarlı Radyoterapi (“Intensity Modulated Radiotherapy”-IMRT) ve Hacimsel Modülasyonlu Ark Tedavisi (“Volumetric Modulated Arc Therapy”-VMAT) planlarını minimum iş akışıyla optimize etmek için bilgi tabanlı modeller (“Knowledge Based Model”–KBM) kullanarak plan kalitesini standart hale getirmeyi amaçlar. KBP, Risk Altındaki Organlar (‟Organ at Risk”-OAR) için ulaşılabilir Doz-Volüm Histogramı (DVH)’nı tahmin eder ve her bir yeni hasta için ideal optimizasyon hedefleri sağlar. KBP modeli, plan kalitesini iyileştirir, plan tutarlılığını koruyarak planlayıcılar arası değişkenliği azaltır ve simülasyondan tedavi başlangıcına dek geçen süreyi kısaltır. Bu derlemede prostat kanserinin VMAT tekniği ile tedavisinde KBP tabanlı yöntemlerin kullanıldığı klinik çalışmaların sonuçları incelendi. “Knowledge-based treatment planning”, “prostate cancer”, “VMAT” anahtar kelimeleri kullanılarak “PubMed” tarama motorunda “Clinical Trial” kategorisindeki İngilizce olarak yayınlanmış makalelerin taranması sonucu ulaşılan beş adet çalışma derleme kapsamına alındı. Bu klinik çalışmaların tümünde temelde KBP modelinin dozimetrik ve mekanik performansını değerlendirmek ve optimize etmek istenmiştir. Bu nedenle her bir kliniğin deneyimine göre hazırlanan manuel planlar, KBP ile oluşturulan otomatik planlar ile karşılaştırılmıştır. Prostat kanserinin VMAT planlamasında KBP kullanımı, doğrulama çalışmalarında, güçlü bir şekilde performans göstermiştir. KBP yöntemleri, plan kalitesi açısından genellikle uzman seviyesindeki planlayıcılara eşdeğerdir ancak ön sonuçlar, önemli ölçüde daha gelişmiş olduklarını göstermektedir. Hedef volüm ile örtüşen OAR volümlerinin dikkate alındığı KBP modellerinin örtüşme volüm histogramı (“overlap volüme histogram”-OVH) rehberliğinde daha hassas ve doğru doz tahminleri yapabileceği düşünülmektedir. KBP yöntemlerinin uygulaması sırasında dozimetrik ve mekanik performansın yanı sıra hastaya özgü kalite güvenirliğini (“Quality Assurance” –QA) doğrulamak da çok önemlidir.


  • Open Access

    A Promising, Novel Radiosensitizer Nanodrug Complex for Oral Cavity Cancer: Cetuximab and Cisplatin-Conjugated Gold Nanoparticles

    by Seniz Inanc Surer, Tarik Bugra Elcitepe, Dogukan Akcay, Ezgi Daskin, Gizem Calibasi Kocal, Zumre Arican Alicikus, Gorkem Eskiizmir, Kerim Yapici, Yasemin Basbinar

    Nanomedicine has provided promising tools for the imaging, diagnosis, and treatment of cancer. Gold nanoparticles (GNPs) may be useful in enhancing the efficacy of radiotherapy, such as radiosensitization, in cancer therapy. To develop a nanodrug complex containing cetuximab (C225, CTX) and cisplatin (CDDP) conjugated with GNPs and to investigate its cytotoxic effects on oral cavity cancer cells when combined with radiotherapy. In vitro cell culture study. The GNPs were synthesized and successfully conjugated with cetuximab and cisplatin. Cell viability was monitored by the xCELLigence real-time cell analysis (RTCA) single-plate (SP) system in GNP-treated UPCI-SCC-131 cells for 48 hours. Cells with/without GNPs were irradiated with 6 MV X-rays, and colony formation was assayed to investigate the long-term effects of GNPs and the nanodrug complex after irradiation on radiotherapy-resistant oral cavity cancer cells. The GNPs entered the tumor cells, and GNP–CDDP (P < .0001) and GNP–CDDP–CTX (P < .0001) were shown to cause a decrease in cell viability. GNP and GNP–CTX combined with radiotherapy led to greater reduction on UPCI-SCC-131 colony numbers, than radiation alone (P = .0369) and radiation with free CTX, with sensitizing enhancement ratios of 1 : 2 and 1 : 9, respectively. The cetuximab and cisplatin-conjugated gold nanodrug complex has a great potential to increase cytotoxicity and overcome resistance to radiotherapy, in the treatment of oral cavity cancer.